RENOTEC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOTEC is an injectable pharmaceutical product approved in 1974 by Bracco, indicating a legacy diagnostic or therapeutic agent with established clinical utility. The specific mechanism of action and indications are not publicly detailed in available data, though the injectable formulation suggests use in specialized clinical settings.
LOE Approaching
Approaching loss of exclusivity signals contraction phase; commercial team focus likely shifting to generic defense or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOTEC offers minimal active career development opportunities given its mature status and approaching LOE. Roles on this product are primarily defensive, focused on compliance, brand protection, and transition planning rather than growth or innovation.
Product Manager (Legacy)Regulatory Affairs Specialist
Worked on RENOTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.